Relative hazard of ESLD during 16 years of follow-up of hemophilia patients infected with HIV and HCV and with known CD4+ lymphocyte counts and hepatitis B status
| Variable . | No. of participants . | ESLD cases (%) . | Relative hazard (95% CI)3-150 . |
|---|---|---|---|
| Age at CD4 testing | 1045 | 105 (10.0) | 1.04 (1.03-1.06) |
| Hepatitis B status | |||
| Chronic antigenemia3-151 | 92 | 19 (20.7) | 8.1 (1.9-35.2) |
| Resolved infection3-151 | 883 | 84 (9.5) | 3.4 (0.8-14.0) |
| Uninfected/vaccinated3-151 | 70 | 2 (2.9) | 1.0 (Referent) |
| CD4+ lymphocyte count | |||
| 0 to 0.199 × 109/L | 207 | 23 (11.1) | 2.1 (1.3-3.3) |
| 0.2 to 0.499 × 109/L | 460 | 50 (10.9) | 1.0 (Referent) |
| 0.5 to 2.195 × 109/L | 378 | 32 (8.5) | 1.0 (Referent) |
| CD8+ lymphocyte count | |||
| 0.012 to 0.499 × 109/L | 346 | 38 (11.0) | Not included |
| 0.5 to 0.899 × 109/L | 419 | 36 (8.5) | Not included |
| 0.9 to 5.403 × 109/L | 280 | 31 (11.1) | Not included |
| Variable . | No. of participants . | ESLD cases (%) . | Relative hazard (95% CI)3-150 . |
|---|---|---|---|
| Age at CD4 testing | 1045 | 105 (10.0) | 1.04 (1.03-1.06) |
| Hepatitis B status | |||
| Chronic antigenemia3-151 | 92 | 19 (20.7) | 8.1 (1.9-35.2) |
| Resolved infection3-151 | 883 | 84 (9.5) | 3.4 (0.8-14.0) |
| Uninfected/vaccinated3-151 | 70 | 2 (2.9) | 1.0 (Referent) |
| CD4+ lymphocyte count | |||
| 0 to 0.199 × 109/L | 207 | 23 (11.1) | 2.1 (1.3-3.3) |
| 0.2 to 0.499 × 109/L | 460 | 50 (10.9) | 1.0 (Referent) |
| 0.5 to 2.195 × 109/L | 378 | 32 (8.5) | 1.0 (Referent) |
| CD8+ lymphocyte count | |||
| 0.012 to 0.499 × 109/L | 346 | 38 (11.0) | Not included |
| 0.5 to 0.899 × 109/L | 419 | 36 (8.5) | Not included |
| 0.9 to 5.403 × 109/L | 280 | 31 (11.1) | Not included |
Relative hazard and 95% CI from proportional hazards model, adjusted for age, hepatitis B status, and CD4+ lymphocyte count. Each participant entered the model at the date of the CD4+ lymphocyte count.
Hepatitis B status defined by serology and vaccination history: Chronic participants had persistent hepatitis B surface antigenemia for at least 6 months; resolved had detectable hepatitis B anticore antibodies or antisurface antibodies with no antecedent hepatitis B vaccination; uninfected had undetectable hepatitis B anticore antibodies or hepatitis B vaccination with negative antecedent hepatitis B serology.